Amgen reported the trial failure of an experimental drug intended to treat Parkinson's disease. A mid-stage trial of 34 patients showed the drug, GDNF, did not meet the goal of improving symptoms over six months compared with a placebo, but Amgen said it is studying the data to determine why the study results differ from a three-year study in the U.K. that shows long-term improvements.

Full Story:

Related Summaries